4.7 Article

Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression

Related references

Note: Only part of the references are listed.
Review Pharmacology & Pharmacy

Understanding and countering opioid-induced respiratory depression

Jordan T. Bateman et al.

Summary: This review aims to provide a comprehensive understanding of the pharmacological mechanisms of opioid-induced respiratory depression, with the goal of improving therapeutic options for opioid overdose and other detrimental effects on breathing. The review discusses the development of tolerance in the respiratory system and differences in the degree of respiratory depression caused by different opioid agonists. Potential future therapeutic agents targeting non-opioid receptors are also explored.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Neurosciences

Pharmacological and genetic manipulations at the μ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice

Li He et al.

Summary: Opioid drugs act by activating the mu-opioid receptor to provide analgesic effects, while potentially leading to side effects such as respiratory depression and tolerance development. Recent studies challenge the prevailing hypothesis that arrestin-3 recruitment contributes to respiratory depression and analgesic tolerance, proposing that future development of safer opioids should target ligands that recruit both G protein and arrestin-3.

NEUROPSYCHOPHARMACOLOGY (2021)

Review Neurosciences

Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics

Travis W. Grim et al.

BIOLOGICAL PSYCHIATRY (2020)

Article Pharmacology & Pharmacy

Morphine-induced respiratory depression is independent of β-arrestin2 signalling

Andrea Kliewer et al.

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Article Biochemistry & Molecular Biology

Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists

Alexander Gillis et al.

SCIENCE SIGNALING (2020)

Article Public, Environmental & Occupational Health

Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018

Nana Wilson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

Review Pharmacology & Pharmacy

Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor

Alexander Gillis et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2020)

Article Neurosciences

Development of vaccines to treat opioid use disorders and reduce incidence of overdose

Marco Pravetoni et al.

NEUROPHARMACOLOGY (2019)

Article Pharmacology & Pharmacy

The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception

Rob Hill et al.

BRITISH JOURNAL OF PHARMACOLOGY (2018)

Article Biochemistry & Molecular Biology

Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics

Cullen L. Schmid et al.

Article Multidisciplinary Sciences

Structure-based discovery of opioid analgesics with reduced side effects

Aashish Manglik et al.

NATURE (2016)

Article Pharmacology & Pharmacy

A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphines

Scott M. DeWire et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)

Review Pharmacology & Pharmacy

Regulation of mu-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance

John T. Williams et al.

PHARMACOLOGICAL REVIEWS (2013)

Article Pharmacology & Pharmacy

Functional Selectivity and Biased Receptor Signaling

Terry Kenakin

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)

Review Multidisciplinary Sciences

Transduction of receptor signals by β-arrestins

RJ Leftowitz et al.

SCIENCE (2005)

Article Pharmacology & Pharmacy

Morphine side effects in beta-arrestin 2 knockout mice

KM Raehal et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)